Brokerages expect QIAGEN (NYSE:QGEN) to announce $0.53 earnings per share (EPS) for the current fiscal quarter, according to Zacks. Four analysts have provided estimates for QIAGEN’s earnings. The lowest EPS estimate is $0.51 and the highest is $0.53. QIAGEN reported earnings per share of $0.58 in the same quarter last year, which would suggest a negative year-over-year growth rate of 8.6%. The company is expected to issue its next earnings report on Tuesday, October 26th.
On average, analysts expect that QIAGEN will report full-year earnings of $2.45 per share for the current year, with EPS estimates ranging from $2.42 to $2.47. For the next fiscal year, analysts anticipate that the business will report earnings of $2.03 per share, with EPS estimates ranging from $1.95 to $2.13. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that follow QIAGEN.
QIAGEN (NYSE:QGEN) last posted its quarterly earnings results on Thursday, July 29th. The company reported $0.67 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.66 by $0.01. The business had revenue of $567.31 million during the quarter, compared to the consensus estimate of $562.35 million. QIAGEN had a net margin of 21.92% and a return on equity of 21.31%. During the same period in the previous year, the firm posted $0.55 earnings per share.
Shares of QGEN traded up $0.36 on Monday, reaching $54.70. 729,348 shares of the company’s stock were exchanged, compared to its average volume of 787,586. The company has a current ratio of 3.58, a quick ratio of 2.90 and a debt-to-equity ratio of 0.65. The stock has a market capitalization of $12.47 billion, a P/E ratio of 26.49, a price-to-earnings-growth ratio of 1.98 and a beta of 0.21. The business has a 50 day moving average price of $52.73 and a two-hundred day moving average price of $50.16. QIAGEN has a 12 month low of $45.33 and a 12 month high of $59.00.
A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Captrust Financial Advisors bought a new position in shares of QIAGEN in the first quarter valued at about $38,000. Dark Forest Capital Management LP bought a new position in shares of QIAGEN in the second quarter valued at about $51,000. Wolverine Asset Management LLC raised its position in shares of QIAGEN by 50.9% in the first quarter. Wolverine Asset Management LLC now owns 1,482 shares of the company’s stock valued at $72,000 after purchasing an additional 500 shares during the period. Standard Family Office LLC raised its position in shares of QIAGEN by 123.1% in the first quarter. Standard Family Office LLC now owns 1,504 shares of the company’s stock valued at $73,000 after purchasing an additional 830 shares during the period. Finally, Altshuler Shaham Ltd bought a new position in shares of QIAGEN in the first quarter valued at about $85,000. Institutional investors and hedge funds own 52.17% of the company’s stock.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Featured Story: Why is the ex-dividend date different from the record date?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for QIAGEN Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for QIAGEN and related companies with MarketBeat.com's FREE daily email newsletter.